Bisphosphonates-related severe pain should not be overlooked
- PDF / 122,968 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 16 Downloads / 176 Views
1
Bisphosphonates-related severe pain should not be overlooked The US FDA has advised healthcare professionals not to overlook the possibility of severe and sometimes incapacitating musculoskeletal pain in patients receiving bisphosphonates. Healthcare professionals may overlook the association between bisphosphonates and severe musculoskeletal pain, which can delay diagnosis and prolong pain and/or impairment, necessitating analgesic use. The severe musculoskeletal pain may develop within days, months or years after bisphosphonate initiation. According to the FDA, this severe musculoskeletal pain is different than the acute phase response characterised by chills, fever, bone pain, muscle pain and arthralgias that sometimes accompanies initial bisphosphonate exposure. The agency has advised healthcare professionals to consider a possibility of bisphosphonate-induced severe musculoskeletal pain and of discontinuing bisphosphonates if severe pain symptoms occur. Prescribers should consider the risks and benefits of bisphosphonate use and patients should immediately contact their doctor if they develop severe musculoskeletal pain during bisphosphonate treatment, says the FDA. US Food and Drug Administration. Information for healthcare professionals: bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). Internet Document : [3 801052445 pages], 7 Jan 2008. Available from: URL: http://www.fda.gov
0114-9954/10/1184-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 12 Jan 2008 No. 1184
Data Loading...
